Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: A multicenter prospective randomized trial

Cancer

Volumn 116, Issue 8, 2010, Pages 1893-1900

  Di Lorenzo, Giuseppe ^a   Perdonà, Sisto ^b   Damiano, Rocco ^c   Faiella, Adriana ^a   Cantiello, Francesco ^c   Pignata, Sandro ^b   Ascierto, Paolo ^b   Simeone, Ester ^b   De Sio, Marco ^d   Autorino, Riccardo ^d  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Bacille Calmette Gu rin; Failure; Gemcitabine; Superficial bladder cancer

Indexed keywords

BCG VACCINE; GEMCITABINE;

AGED; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTECTOMY; DERMATITIS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSURIA; FEMALE; FEVER; HEMATURIA; HUMAN; ILEOSTOMY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RETREATMENT; THROMBOCYTOPENIA; TREATMENT DURATION; URETEROSTOMY; VOMITING;

ADMINISTRATION, INTRAVESICAL; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BCG VACCINE; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; RETREATMENT; TREATMENT FAILURE; URINARY BLADDER NEOPLASMS;

EID: 77950986756     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24914     Document Type: Article

References (28)

1. Sylvester RJ, van der Meijden APM, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a combined analysis of the published results of randomized clinical trials. J Urol. 2002;168:1964-1970.
2. Bohle A, Bock PR. Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumour progression. Urology. 2004;63:682-686. (Pubitemid 38479409)
3. Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2003;169:90-95. (Pubitemid 35461559)
4. Witjes JA. Management of BCG failures in superficial bladder cancer: a review. Eur Urol. 2006;49:790-797.
5. Sylvester RJ, van der Meijden APM, Witjes JA, Kurth KH. Bacillus Calmette-Guerin versus chemotherapy in the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol. 2005;174:86-92.
6. Huguet J, Crego M, Sabate S, Salvador J, Palou J, Villavicencio H. Cystectomy in patients with high risk superficial bladder tumours who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Eur Urol. 2005;48:53-59. (Pubitemid 40838628)
7. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2008;54:303-314.
8. Herr HW, Dalbagni G. Defining bacillus Calmette-Guerin refractory superficial bladder tumours. J Urol. 2003;169:1706-1708. (Pubitemid 36443476)
9. Joudi FN, O'Donnell MA. Second-line intravesical therapy versus cystectomy for bacille Calmette-Guerin (BCG) failures. Curr Opin Urol. 2004;14:271-275.
10. El Karak F, Flechon A. Gemcitabine in bladder cancer. Expert Opin Pharmacother. 2007;8:3251-3256.
11. Gontero P, Marini L, Frea B. Intravesical gemcitabine for superficial bladder cancer: rationale for a new treatment option. BJU Int. 2005;96:970-976. (Pubitemid 41531397)
12. Dalbagni G, Russo P, Sheinfeld J, et al. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol. 2002;20:3193-3198. (Pubitemid 34831514)
13. Dalbagni G, Russo P, Bochner B, et al. Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol. 2006;24:2729-2734. (Pubitemid 46630569)
14. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from 7 EORTC trials. Eur Urol. 2006;49:466-475. (Pubitemid 43259554)
15. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176-181. (Pubitemid 36962641)
16. Morabito F, Rossi R, Graziano ME, et al. Multicenter study on the use of gemcitabine to prevent recurrence of multiple-recurring superficial bladder tumors following intravesical antiblastic agents and/or BCG: evaluation of tolerance. Arch Ital Urol Androl. 2006;78:1-4. (Pubitemid 43736065)
17. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol. 2001;19:666-675. (Pubitemid 32120143)
18. Sarosdy MF, Manyak MJ, Sagalowsky AI, et al. Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guerin. Urology. 1998;5:226-231.
19. O'Donnell MA, Lilli K, Leopold C. Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J Urol. 2004;172:888-893. (Pubitemid 39096415)
20. Van Der Heijden AG, Kiemeney LA, Gofrit ON, et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol. 2004;46:65-72.
21. Waidelich R, Stepp H, Baumgartner R, Weninger E, Hofstetter A, Kriegmair M. Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. J Urol. 2001;165:1904-1907. (Pubitemid 32453493)
22. Steinberg G, Bahnson R, Brosman S, et al. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. J Urol. 2000;163:761-767. (Pubitemid 30091611)
23. Bartoletti R, Cai T, Gacci M, et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a phase II prospective multicenter study. Urology. 2005;66:726-731. (Pubitemid 41440812)
24. Gacci M, Bartoletti R, Cai T, et al. Intravesical gemcitabine in BCG-refractory T1G3 transitional cell carcinoma of the bladder: a pilot study. Urol Int. 2006;76:106-111. (Pubitemid 43872556)
25. Gunelli R, Bercovich E, Nanni O, et al. Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study. Br J Cancer. 2007;97:1499-1504. (Pubitemid 350175858)
26. Gontero P, Frea B. Actual experience and future development of gemcitabine in superficial bladder cancer. Ann Oncol. 2006;17(suppl 5):123-128. (Pubitemid 43985221)
27. Hendricksen K, Witjes JA. Intravesical gemcitabine: an update of clinical results. Curr Opin Urol. 2006;16:361-366. (Pubitemid 44231713)
28. Bassi P, De Marco V, Tavolini IM, et al. Pharmacokinetic study of intravesical gemcitabine in carcinoma in situ of the bladder refractory to bacillus Calmette-Guerin therapy. Urol Int. 2005;75:309-313. (Pubitemid 41752577)